FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 317:1200-1209 November 5, 1987 Number 19 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

The Zollinger-Ellison syndrome, although uncommon, is not rare, and most patients with the disorder present with clinical manifestations similar to those of patients with common peptic ulcer. Early studies emphasized death due to complications of massive gastric acid hypersecretion. However, with the availability of potent antisecretory agents to control acid secretion, death is now more frequently associated with the metastatic potential of slowly growing but malignant gastrinomas. Therefore, physicians should maintain a high degree of suspicion of the Zollinger-Ellison syndrome in assessing patients with either chronic peptic ulcer or unexplained secretory diarrhea. An evaluation aimed at early diagnosis of the Zollinger-Ellison syndrome should be instituted in such patients and should begin with a determination of the fasting serum gastrin level. At least 50 percent of patients with gastrinoma will have nondiagnostic serum gastrin concentrations and will therefore require provocative testing to establish the correct diagnosis. After the presence of the syndrome is established, patients should be treated with a potent antisecretory agent in doses sufficient to reduce basal acid output to less than 10 mmol in the hour preceding administration of the next dose. Although some patients may be maintained satisfactorily in this manner for extended periods, an approach aimed at tumor localization and extirpation is recommended in most patients. Preoperative evaluation should begin with CT scanning with intravenous contrast material. Selective angiography, and occasionally, portal venous sampling for gastrin, should be performed if the location and extent of tumor remain in question. If metastatic disease is demonstrated, or if MEN-I is present, surgery aimed at tumor resection, although it is occasionally effective, will probably be unsuccessful. Because of the considerable morbidity and mortality associated with pancreatoduodenectomy, it should not be performed for unresectable tumor in the head of the pancreas. In other patients with the Zollinger-Ellison syndrome, exploratory surgery should be performed; this should include a careful search for, and resection of, all pancreatic and extrapancreatic gastrinomas. With this approach, it is likely that at least 20 percent of all patients with the Zollinger-Ellison syndrome can be cured.

Source Information

Harvard Digestive Diseases Center, Beth Israel Hospital, Boston, MA.

This article has been cited by other articles:

• Kaltsas, G. A., Besser, G. M., Grossman, A. B. (2004). The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors. Endocr. Rev. 25: 458-511 [Abstract] [Full Text]  
• Goetze, J. P., Rehfeld, J. F. (2003). Impact of Assay Epitope Specificity in Gastrinoma Diagnosis. Clin. Chem. 49: 333-334 [Full Text]  
• Berger, A. C., Gibril, F., Venzon, D. J., Doppman, J. L., Norton, J. A., Bartlett, D. L., Libutti, S. K., Jensen, R. T., Alexander, H. R. (2001). Prognostic Value of Initial Fasting Serum Gastrin Levels in Patients With Zollinger-Ellison Syndrome. JCO 19: 3051-3057 [Abstract] [Full Text]  
• Debas, H. T., Mulvihill, S. J. (1994). Neuroendocrine Gut Neoplasms: Important Lessons From Uncommon Tumors. Arch Surg 129: 965-972 [Abstract]  
• London, J. F., Frucht, H., Doppman, J. L., Maton, P. N., Gardner, J. D., Jensen, R. T. (1989). Zollinger-Ellison Syndrome in the Intensive Care Setting. J Intensive Care Med 4: 272-283 [Abstract]  
• Wolfe, M. M. (1989). Diagnosis of Gastrinoma: Much Ado about Nothing?. ANN INTERN MED 111: 697-699 [Abstract]